Home » Stocks » KIN

Kindred Biosciences, Inc. (KIN)

Stock Price: $4.64 USD -0.10 (-2.01%)
Updated Feb 25, 2021 1:56 PM EST - Market open
Market Cap 191.73M
Revenue (ttm) 42.61M
Net Income (ttm) -26.63M
Shares Out 39.31M
EPS (ttm) -0.68
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 25
Last Price $4.64
Previous Close $4.73
Change ($) -0.10
Change (%) -2.01%
Day's Open 4.73
Day's Range 4.61 - 4.79
Day's Volume 269,805
52-Week Range 3.11 - 11.93

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 2 months ago

SAN FRANCISCO, Dec. 21, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive re...

Business Wire - 2 months ago

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) today announced an agreement with Kindred Biosciences (NASDAQ: KIN) to acquire exclusive global rights to KIND...

Other stocks mentioned: ELAN
PRNewsWire - 2 months ago

SAN FRANCISCO, Dec. 2, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Dr. Ric...

Seeking Alpha - 3 months ago

Kindred Biosciences, Inc. (KIN) CEO Richard Chin on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Kindred Bio (KIN) delivered earnings and revenue surprises of 0.00% and 82.98%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

PRNewsWire - 3 months ago

SAN FRANCISCO, Nov. 9, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial re...

Zacks Investment Research - 3 months ago

Kindred Bio (KIN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 3 months ago

SAN FRANCISCO, Oct. 28, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will release its third quar...

PRNewsWire - 5 months ago

SAN FRANCISCO, Sept. 16, 2020 /PRNewswire/ -- Kindred Biosciences, Inc.

PRNewsWire - 5 months ago

SAN FRANCISCO, Sept. 9, 2020 /PRNewswire/ -- Kindred Biosciences, Inc.

Seeking Alpha - 5 months ago

Two Sample Breakout Stocks for Week 36 with better than 10% short-term upside potential. Now up an average 183.6% YTD.

Other stocks mentioned: AAPL, CVX, EXK, HD, JNJ, MRK, PFE, VZ, WMT
Zacks Investment Research - 5 months ago

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

Other stocks mentioned: AWR, CLRB, CVEO, POR
Seeking Alpha - 6 months ago

Kindred Biosciences, Inc.'s (KIN) CEO Richard Chin on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Kindred Bio (KIN) delivered earnings and revenue surprises of 333.33% and 100.19%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 6 months ago

Kindred Bio (KIN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 7 months ago

Kindred Bio (KIN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research - 7 months ago

Investors need to pay close attention to Kindred Biosciences (KIN) stock based on the movements in the options market lately.

PRNewsWire - 8 months ago

SAN FRANCISCO, June 8, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced a plan to en...

Seeking Alpha - 9 months ago

Kindred Biosciences, Inc. (KIN) CEO Richard Chin on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

Kindred Bio (KIN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 11 months ago

Kindred Biosciences, Inc. (KIN) CEO Richard Chin on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 11 months ago

Kindred Bio (KIN) delivered earnings and revenue surprises of -5.26% and -3.38%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 11 months ago

Kindred Bio (KIN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 1 year ago

Kindred Biosciences, Inc. (KIN) CEO Richard Chin on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Kindred Bio (KIN) delivered earnings and revenue surprises of -11.43% and -28.77%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Seeking Alpha - 1 year ago

Kindred Biosciences' (KIN) CEO Richard Chin on Q2 2019 Results - Earnings Call Transcript

24/7 Wall Street - 1 year ago

While most of Wall Street focuses on large and mega cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: ADAP, CLDR, FLMN, ZNGA
Seeking Alpha - 1 year ago

Kindred Biosciences'(KIN) CEO Richard Chin on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Kindred Bio (KIN) delivered earnings and revenue surprises of 0.00% and -73.62%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

The Motley Fool - 1 year ago

KIN earnings call for the period ending December 31, 2018.

About KIN

Kindred Biosciences, a biopharmaceutical company, is developing biologics that focus on the lives of pets. The company has a pipeline of novel biologics in development across various therapeutic classes and intellectual property portfolio. Its programs under development include interleukin-31 and interleukin-4R for canine atopic dermatitis; KIND-030 for parvovirus in dogs; KIND-510a for the control of non-regenerative anemia in cats; anti-TNF antibody for inflammatory bowel disease in dogs; and other biologics candidates. The company was founde... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Dec 12, 2013
CEO
Richard Chin
Employees
156
Stock Exchange
NASDAQ
Ticker Symbol
KIN
Full Company Profile

Financial Performance

In 2019, KIN's revenue was $4.26 million, an increase of 116.48% compared to the previous year's $1.97 million. Losses were -$61.39 million, 23.5% more than in 2018.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for KIN stock is "Buy." The 12-month stock price forecast is 10.89, which is an increase of 134.95% from the latest price.

Price Target
$10.89
(134.95% upside)
Analyst Consensus: Buy